beat top line ep estim guidanc updat lartruvo ph
failur loxo acquisit prior guidanc expect forecast
remaind elanco split-off
ep estim consensu ep
guidanc first issu decemb updat failur ph lartruvo
trial pend loxo oncolog acquisit prior
last publish ep estim review includ lartruvo/loxo
impact compani guidanc estim includ elanco full year
sale forecast
consensu product ahead estim includ ciali cymbalta
humalog strattera alimta jardianc taltz tradjenta cyramza olumi
combin forecast product estim includ verzenio
effient basaglar zyprexa trulic combin
light sale guidanc trim prior last
publish estim
gpm estim sg
estim forecast net non-op
expens greater estim tax rate
forecast share count estim updat
 guidanc gpm sg unchang vs prior
oper margin vs prior inc/exp
expens vs prior expens expens tax rate
vs prior
verzenio ph ii data monarch mbc w/herceptin taltz ph iv data
ixora-r vs tremfya psoriasi ph data nr axspa approval/eu file
radiograph axspa emgal cgrp approval/eu file episod cluster headach
lasmiditan approv acut migrain olumi initi ph alopecia areata
cyramza /eu approv afp-high ph data egfr nsclc
relay jardianc initi ph ckd data chf exercis studi file
glucagon nasal /eu approv hypoglycemia tanezumab w/pfe ph data oa
pain l-t safeti clbp tradjenta ph data cv outcom studi carolina trulic
full cv outcom rewind data ada ph data
libretto /file ret fusion cancer mirikizumab ph ii data/ph initi crohn
pegilodecakin ph ii data nsclc tirzepatid initi ph obes ph ii nash
connect file elanco full separ via exchang offer may
immin loxo acquisit close alimta patent appeal rule
pleas see page report import disclosur
number promis new drug current roll hand late-stag agent
pois launch next year strengthen loxo asset give us
confid above-averag sale ep growth prospect estim ep
compound-annual-growth-rate compar industri averag dividend yield attract
verzenio breast cancer emgal
perform diabet busi
notabl trulic
full trulic rewind data ada
close loxo acquisit
separ elanco
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
margin expans sooner greater
alimta declin rapidli
margin expans delay reduc
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas oncolog
among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
anim divest stake elanco via share exchang
cowen compani
good mm cowen
cowen compani www lilli com
cowen compani
cowen compani
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
